The Who, What, Where, When and Sometimes, Why.

Facts and Statistics References

  1. National Cancer Institute. Breast cancer treatment (adult) (PDQ®) – patient version. https://www.cancer.gov/types/breast/patient/breast-treatment-pdq, 2022.
  2. Osborne MP and Boolbol SK. Chapter 1. Breast anatomy and development, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  3. Lee CI and Elmore JG. Chapter 10. Breast cancer screening, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  4. American Cancer Society. Invasive Breast Cancer (IDC/ILC). https://www.cancer.org/cancer/breast-cancer/about/types-of-breast-cancer/invasive-breast-cancer.html, 2021.
  5. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Breast cancer V.2.2022. http://www.nccn.org/, 2022.
  6. Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J. Predictors of an invasive breast cancer recurrence after DCIS: a systematic review and meta-analyses. Cancer Epidemiol Biomarkers Prev. 28(5):835-845, 2019.
  7. Mariotto AB, Etzioni R, Hurlbert M, PenberthyL, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 26(6):809-815, 2017.
  8. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast cancer- Stage distribution of SEER incidence cases, 2010-2019 by sex, all races, all ages. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  9. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast cancer – SEER survival rates by time since diagnosis, 2000-2018, by sex, all races, all ages, distant. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  10. Centers for Disease Control and Prevention. What are the symptoms of breast cancer? http://www.cdc.gov/cancer/breast/basic_info/symptoms.htm, 2021.
  11. American Cancer Society. Breast cancer signs and symptoms. https://www.cancer.org/cancer/breast-cancer/about/breast-cancer-signs-and-symptoms.html, 2022.
  12. American Cancer Society. Breast biopsy. https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/breast-biopsy.html, 2022.
  13. Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 353(3):229-37, 2005.
  14. Dyrstad SW, Yan Y, Fowler AM, Colditz GA. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res Treat. 149(3):569-75, 2015.
  15. Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol. 3(1):36-41, 2017.
  16. Lilleborge M, Falk RS, Russnes H, Sauer T, Ursin G, Hofvind S. Risk of breast cancer by prior screening results among women participating in BreastScreen Norway. Cancer. 125(19):3330-3337, 2019.
  17. Rohan TE, Negassa A, Chlebowski RT, et al. Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst. 100(8):563-71, 2008.
  18. Berkey CS, Tamimi RM, Rosner B, Frazier AL, Colditz GA. Young women with family history of breast cancer and their risk factors for benign breast disease. Cancer. 118(11):2796-803, 2012.
  19. Berkey CS, Willett WC, Frazier AL, et al. Prospective study of adolescent alcohol consumption and risk of benign breast disease in young women. Pediatrics. 125(5):e1081-7, 2010.
  20. Liu Y, Tamimi RM, Berkey CS, et al. Intakes of alcohol and folate during adolescence and risk of proliferative benign breast disease. Pediatrics. 129(5):e1192-8, 2012.
  21. Liu Y, Colditz GA, Rosner B, et al. Alcohol intake between menarche and first pregnancy: a prospective study of breast cancer risk. J Natl Cancer Inst. 105(20):1571-8, 2013.
  22. Berkey CS, Tamimi RM, Willett WC, et al. Adolescent alcohol, nuts, and fiber: combined effects on benign breast disease risk in young women. NPJ Breast Cancer. 6(1):61, 2020.
  23. Boeke CE, Tamimi RM, Berkey CS, et al. Adolescent carotenoid intake and benign breast disease. Pediatrics. 133(5):e1292-8, 2014.
  24. Baer HJ, Schnitt SJ, Connolly JL, et al. Early life factors and incidence of proliferative benign breast disease. Cancer Epidemiol Biomarkers Prev. 14(12):2889-97, 2005.
  25. Berkey CS, Tamimi RM, Willett WC, et al. Dietary intake from birth through adolescence in relation to risk of benign breast disease in young women. Breast Cancer Res Treat. 177(2):513-525, 2019.
  26. Berkey CS, Rosner B, Tamimi RM, et al. Body size from birth through adolescence in relation to risk of benign breast disease in young women. Breast Cancer Res Treat. 162(1):139-149, 2017.
  27. Ahlgren M, Melbye M, Wohlfahrt J, Sørensen TI. Growth patterns and the risk of breast cancer in women. N Engl J Med. 351(16):1619-26, 2004.
  28. Baer HJ, Tworoger SS, Hankinson SE, Willett WC. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol. 171(11):1183-94, 2010.
  29. Harris HR, Tamimi RM, Willett WC, Hankinson SE, Michels KB. Body size across the life course, mammographic density, and risk of breast cancer. Am J Epidemiol. 174(8):909-18, 2011.
  30. Fagherazzi G, Guillas G, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S. Body shape throughout life and the risk for breast cancer at adulthood in the French E3N cohort. Eur J Cancer Prev. 22(1):29-37, 2013.
  31. Keinan-Boker L, Levine H, Derazne E, Molina-Hazan V, Kark JD. Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women. Breast Cancer Res Treat. 158(1):157-67, 2016.
  32. Horn-Ross PL, Canchola AJ, Bernstein L, Neuhausen SL, Nelson DO, Reynolds P. Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort. Breast Cancer Res. 18(1):132, 2016.
  33. Aarestrup J, Bjerregaard LG, Meyle KD, et al. Birthweight, childhood overweight, height and growth and adult cancer risks: a review of studies using the Copenhagen School Health Records Register. Int J Obes (Lond). 44(7):1546-1560, 2020.
  34. Twig G, Yaniv G, Levine H, et al. Body-mass index in 2.3 million adolescents and cardiovascular death in adulthood. N Engl J Med. 374(25):2430-40, 2016.
  35. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Breast cancer screening and diagnosis. Version 1.2021. http://www.nccn.org, 2021.
  36. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology: Breast cancer risk reduction. Version 1.2020. http://www.nccn.org, 2020.
  37. Laronga C, Tollin S, Mooney B. Breast cysts-clinical manifestations, diagnosis and management. In: Chagpar AB and Chen W, eds. UpToDate. Waltham, MA, UpToDate, 2022.
  38. Webb PM, Byrne C, Schnitt SJ, et al. A prospective study of diet and benign breast disease. Cancer Epidemiol Biomarkers Prev. 13(7):1106-13, 2004.
  39. Sabel MS. Overview of benign breast diseases. In: Chagpar AB and Chen W, eds. UpToDate. Waltham, MA, UpToDate, 2021.
  40. Collins LC and Schnitt SJ. Chapter 9. Pathology of benign breast disorders, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  41. Moseley T, Desai B, Gary J Whitman GJ, et al. Benign breast intraductal papillomas without atypia at core needle biopsies: is surgical excision necessary? Ann Surg Oncol. 28(3):1347-1355, 2021.
  42. National Cancer Institute. Breast changes and conditions. https://www.cancer.gov/types/breast/breast-changes, 2019.
  43. Kabat GC, Jones JG, Olson N, et al. A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control. 21(6):821-8, 2010.
  44. Visscher DW, Nassar A, Degnim AC, et al. Sclerosing adenosis and risk of breast cancer. Breast Cancer Res Treat. 144(1):205-12, 2014.
  45. Sanders ME, Page DL, Simpson JF, Schuyler PA, Dale Plummer W, Dupont WD. Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. Cancer. 106(7):1453-61, 2006.
  46. Berg JC, Visscher DW, Vierkant RA, et al. Breast cancer risk in women with radial scars in benign breast biopsies. Breast Cancer Res Treat. 108(2):167-74, 2008.
  47. Aroner SA, Collins LC, Connolly JL, et al. Radial scars and subsequent breast cancer risk: results from the Nurses’ Health Studies. Breast Cancer Res Treat. 139(1):277-85, 2013.
  48. Quinn EM, Dunne E, Flanagan F, et al. Radial scars and complex sclerosing lesions on core needle biopsy of the breast: upgrade rates and long-term outcomes. Breast Cancer Res Treat. 183(3):677-682, 2020.
  49. American Cancer Society. Phyllodes tumors of the breast. https://www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions/phyllodes-tumors-of-the-breast.html, 2022.
  50. Grau AM, Chakravarthy AB, Chugh R. Phyllodes tumors of the breast. In: Pierce LJ, Hayes DF, Chagpar AB, Chen W, eds. UpToDate. Waltham, MA, UpToDate, 2022.
  51. American Cancer Society. Fat necrosis and oil cysts in the breasts. https://www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions/fat-necrosis-and-oil-cysts-in-the-breast.html, 2022.
  52. American Cancer Society. Mastitis. https://www.cancer.org/cancer/breast-cancer/non-cancerous-breast-conditions/mastitis.html, 2022.
  53. American Cancer Society. Cancer Facts and Figures 2022. Atlanta, GA: American Cancer Society, 2022.
  54. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted incidence rates, 2000-2019, by sex, observed SEER incidence rate, all races, all ages, all stages. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  55. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted mortality rates, 2000-2019, by sex, all races, all ages. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  56. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted incidence rates, 2000-2019, by race/ethnicity, observed SEER incidence rate, male, all ages, all stages. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  57. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted mortality rates, 2000-2019, by race/ethnicity, male, all ages. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  58. Howlader N, Noone AM, Krapcho M, et al. (editors). Cancer Statistics Review, 1975-2018. Table 1.11: Median age of cancer patients at diagnosis, 2014-2018, by primary cancer site, race and sex. National Cancer Institute. Bethesda, MD. Accessed on May 27, 2021. https://seer.cancer.gov/csr/1975_2018/, 2021.
  59. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted incidence rates, 2000-2019, by sex, observed SEER incidence rates, all races, all ages, all stages. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  60. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted mortality rates, 2000-2019, by sex, all races, all ages. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  61. American Cancer Society. Breast Cancer Facts and Figures 2019-2020. Atlanta, GA: American Cancer Society, 2019.
  62. Kerlikowske K, Miglioretti DL, Buist DSM, Walker R, Carney PA for the National Cancer Institute-Sponsored Breast Cancer Surveillance Consortium. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst. 99(17):1335-9, 2007.
  63. Chlebowski RT, Kuller LH, Prentice RL, et al. for the WHI Investigators. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med. 5;360(6):573-87, 2009.
  64. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2022. CA Cancer J Clin. 72(1):7-33, 2022.
  65. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Long-term trends in SEER age-adjusted mortality rates, 1975-2019, by sex, all races, all ages. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  66. American Cancer Society. Cancer Facts and Figures for African Americans 2022-2024. Atlanta, GA: American Cancer Society, 2022.
  67. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – 5-year age-adjusted incidence rates, 2015-2019, by race/ethnicity, female, all ages, all stages. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  68. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted incidence rates, 2000-2019, by race/ethnicity, observed SEER incidence rate, female, all ages, all stages. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  69. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted mortality rates, 2000-2019, by race/ethnicity, female, all ages. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  70. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Long-term trends in SEER age-adjusted incidence rates, 1975-2019, by race/ethnicity, observed SEER incidence rates, female, all ages. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  71. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Long-term trends in SEER age-adjusted mortality rates, 1975-2019, by race/ethnicity, female, all ages. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  72. American Cancer Society. Cancer Facts and Figures 2009. Atlanta, GA: American Cancer Society, 2009.
  73. American Cancer Society. Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society, 2016.
  74. The United States Census Bureau. National population totals: 2010-2020 – Annual estimates of the resident population for the nation and states. https://www.census.gov/programs-surveys/popest/technical-documentation/research/evaluation-estimates/2020-evaluation-estimates/2010s-totals-national.html, 2021.
  75. The United States Census Bureau. The nation’s median age continues to rise. https://www.census.gov/library/visualizations/2017/comm/median-age.html, 2021.
  76. International Agency for Research on Cancer (IARC) and World Health Organization (WHO). GLOBOCAN 2020: Breast. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf, 2020.
  77. Fitzmaurice C, Allen C, Barber RM, et al. for the Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 3(4):524-548, 2017.
  78. International Agency for Research on Cancer (IARC) and World Health Organization (WHO). Press release no. 292: Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020. https://www.iarc.fr/wp-content/uploads/2020/12/pr292_E.pdf, 2020.
  79. International Agency for Research on Cancer (IARC) and World Health Organization (WHO). Cancer today. https://gco.iarc.fr/today/online-analysis-multi-bars, 2020.
  80. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast cancer – Recent trends in SEER age-adjusted incidence rates, 2004-2019, by race/ethnicity, observed SEER incidence rate, female, all ages, distant. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  81. Weiss A, Chavez-MacGregor M, Lichtensztajn DY, et al. Validation study of the American Joint Committee on Cancer eighth edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol. 4(2):203-209, 2018.
  82. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures, 2021-2022. Atlanta, GA: American Cancer Society, 2021.
  83. U.S. Centers for Medicare & Medicaid Services. Preventive care benefits for women. https://www.healthcare.gov/preventive-care-women/, 2022.
  84. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – 5-year age-adjusted mortality rates, 2015-2019, by race/ethnicity, female, all ages. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  85. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – People alive with cancer (U.S. prevalence) on January 1, 2019, by race/ethnicity, female, all ages, <= 27 years since diagnosis. Accessed on April 20, 2022. https://seer.cancer.gov/explorer/, 2022.
  86. Melkonian SC, Jim MA, Haverkamp D, et al. Disparities in cancer incidence and trends among American Indians and Alaska Natives in the United States, 2010-2015. Cancer Epidemiol Biomarkers Prev. 28(10):1604-1611, 2019.
  87. Gopalani SV, Janitz AE, Martinez SA, Gutman P, Khan S, Campbell JE. Trends in cancer incidence among American Indians and Alaska Natives and non-Hispanic whites in the United States, 1999-2015. Epidemiology. 31(2):205-213, 2020.
  88. White A, Richardson LC, Li C, Ekwueme DU, Kaur JS. Breast cancer mortality among American Indian and Alaska Native women, 1990-2009. Am J Public Health. 104 Suppl 3:S432-8, 2014.
  89. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – SEER 5-year relative survival rates, 2012-2018, by race/ethnicity, female, all ages, all stages. Accessed on April 19, 2022. https://seer.cancer.gov/explorer/, 2022.
  90. Hendrick RE, Monticciolo DL, Biggs KW, Malak SF. Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women. Cancer. 127(23):4384-4392, 2021.
  91. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 336: 1401-8, 1997.
  92. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 25(11):1329-33, 2007.
  93. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 98(8):1457-66, 2008.
  94. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 317(23):2402-2416, 2017.
  95. Engel C, Fischer C, Zachariae S, et al. for the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. Int J Cancer. 146(4):999-1009, 2020.
  96. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Genetic/familial high-risk assessment—breast, ovarian and pancreatic cancer. Version 2.2022. http://www.nccn.org, 2022.
  97. National Cancer Institute. Genetics of breast and gynecologic cancers (PDQ®) – health professional version. https://www.cancer.gov/types/breast/hp/breast-ovarian-genetics-pdq, 2022.
  98. Tai YC, Domchek S, Parmigiani G, Chen S. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 99(23):1811-4, 2007.
  99. Lecarpentier J, Silvestri V, Kuchenbaecker KB, et al. Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores. J Clin Oncol. 35(20):2240-2250, 2017.
  100. Silvestri V, Leslie L, Barnes DR, et al. Characterization of the cancer spectrum in men with germline BRCA1 and BRCA2 pathogenic variants: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 6(8):1218-1230, 2020.
  101. Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 66(3):182-202, 2016.
  102. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted incidence rates, 2000-2019, by race/ethnicity, observed SEER incidence rate, female, ages 15-39, all stages. Accessed on April 20, 2022. https://seer.cancer.gov/explorer/, 2022.
  103. Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 313(2):165-73, 2015.
  104. Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML. Does race predict survival for women with invasive breast cancer? Cancer. 125(18):3139-3146, 2019.
  105. Ko NY, Hong S, Winn RA, Calip GS. Association of insurance status and racial disparities with the detection of early-stage breast cancer. JAMA Oncol. 6(3):385-392, 2020.
  106. American Cancer Society. Cancer Facts and Figures for Hispanics/Latinos, 2021-2023. Atlanta, GA: American Cancer Society, 2021.
  107. Austin SB, Pazaris MJ, Rosner B, Bowen D, Rich-Edwards J, Spiegelman D. Application of the Rosner-Colditz risk prediction model to estimate sexual orientation group disparities in breast cancer risk in a U.S. cohort of premenopausal women. Cancer Epidemiol Biomarkers Prev. 21(12):2201-8, 2012.
  108. Boehmer U, Miao X, Linkletter C, Clark MA. Adult health behaviors over the life course by sexual orientation. Am J Public Health. 102(2):292-300, 2012.
  109. Azagba S, Shan L, Latham K. Overweight and obesity among sexual minority adults in the United States. Int J Environ Res Public Health. 16(10): 1828, 2019.
  110. Charlton BM, Farland LV, Boehmer U, et al. Sexual orientation and benign breast disease in a cohort of U.S. women. Cancer Causes Control. 31(2):173-179, 2020.
  111. Lee M, Jenkins WD, Boakye EA. Cancer screening utilization by residence and sexual orientation. Cancer Causes Control. 31(10):951-964, 2020.
  112. Williams AD, Bleicher RJ, Ciocca RM. Breast cancer risk, screening, and prevalence among sexual minority women: an analysis of the National Health Interview Survey. LGBT Health. 7(2):109-118, 2020.
  113. de Blok CJM, Wiepjes CM, Nota NM, et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ. 365:l1652, 2019.
  114. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 93:1633-7, 2001.
  115. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. (11):CD002748, 2010.
  116. Hartmann LC, Lindor NM. The role of risk-reducing surgery in hereditary breast and ovarian cancer. N Engl J Med. 374(5):454-68, 2016.
  117. Brown A, Lourenco AP, Niell BL, et al. for the Expert Panel on Breast Imaging. ACR Appropriateness Criteria® transgender breast cancer screening. J Am Coll Radiol. 18(11S):S502-S515, 2021.
  118. American College of Radiology. ACR Appropriateness Criteria: Transgender breast cancer screening. https://acsearch.acr.org/docs/3155692/Narrative/, 2021.
  119. National Cancer Institute. Cancer Stat Facts: Female breast cancer. https://seer.cancer.gov/statfacts/html/breast.html, 2022.
  120. National Cancer Institute. Breast cancer treatment during pregnancy. https://www.cancer.gov/types/breast/hp/pregnancy-breast-treatment-pdq, 2019.
  121. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – SEER 5-year relative survival rates, 2012-2018, by stage at diagnosis, female, all races, all ages. Accessed on April 20, 2022. https://seer.cancer.gov/explorer/, 2022.
  122. American Cancer Society. Key statistics for breast cancer in men. https://www.cancer.org/cancer/breast-cancer-in-men/about/key-statistics.html, 2022.
  123. National Cancer Institute. Male breast cancer treatment-patient version. https://www.cancer.gov/types/breast/patient/male-breast-treatment-pdq, 2022.
  124. American Cancer Society. Can breast cancer in men be found early? https://www.cancer.org/cancer/breast-cancer-in-men/detection-diagnosis-staging/detection.html, 2018.
  125. American Cancer Society. Signs and symptoms of breast cancer in men. https://www.cancer.org/cancer/breast-cancer-in-men/detection-diagnosis-staging/signs-symptoms.html, 2018.
  126. Chavez-Macgregor M, Clarke CA, Lichtensztajn D, Hortobagyi GN, Giordano SH. Male breast cancer according to tumor subtype and race: A population-based study. Cancer. 119(9):1611-7, 2013.
  127. Gradishar WJ and Ruddy KJ. Breast cancer in men. In: Chagpar AB, Hayes DF and Vora SR, eds. UpToDate. Waltham, MA, UpToDate, 2022.
  128. Yadav S, Karam D, Bin Riaz I, et al. Male breast cancer in the United States: treatment patterns and prognostic factors in the 21st century. Cancer. 126(1):26-36, 2020.
  129. Braunstein GD and Anawalt BD. Epidemiology, pathophysiology, and causes of gynecomastia. In: Mastumoto AM and Martin KA, eds. UpToDate. Waltham, MA, UpToDate, 2022.
  130. Braunstein GD and Anawalt BD. Management of gynecomastia. In: Mastumoto AM and Martin KA, eds. UpToDate. Waltham, MA, UpToDate, 2022.
  131. Brinton LA, Carreon JD, Gierach GL, McGlynn KA, Gridley G. Etiologic factors for male breast cancer in the U.S. Veterans Affairs medical care system database. Breast Cancer Res Treat. 119(1):185-92, 2010.
  132. Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer: Male Breast Cancer Pooling Project results. J Natl Cancer Inst. 106(3):djt465, 2014.
  133. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 22(4):735-42, 2004.
  134. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Risk from birth over time, 2017-2019, by risk type, male, all races. Accessed on April 25, 2022. https://seer.cancer.gov/explorer/, 2022.
  135. Leongamornlert D, Mahmud N, Tymrakiewicz M, et al. Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer. 106(10):1697-701, 2012.
  136. Oh M, Alkhushaym N, Fallatah S, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 79(8):880-895, 2019.
  137. Orr N, Lemnrau A, Cooke R, et al. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet. 44(11):1182-4, 2012.
  138. Silvestri V, Zelli V, Valentini V, et al. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer. 123(2):210-218, 2017.
  139. Rizzolo P, Zelli V, Silvestri V, et al. Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy. Int J Cancer. 145(2):390-400, 2019.
  140. Hassett MJ, Somerfield MR, Baker ER. Management of male breast cancer: ASCO guideline. J Clin Oncol. 38(16):1849-1863, 2020.
  141. Thorlacius S, Sigurdsson S, Bjarnadottir H, et al. Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet. 60(5): 1079–1084, 1997.
  142. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2022-2024. Atlanta, GA: American Cancer Society, 2022.
  143. National Cancer Institute. Dictionary of cancer terms. https://www.cancer.gov/publications/dictionaries/cancer-terms, 2022.
  144. American Cancer Society. Breast Cancer Facts and Figures 2022-2024. Atlanta, GA: American Cancer Society, 2022.
  145. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted mortality rates, 2000-2020, by sex, all races, all ages. Accessed on October 11, 2022. https://seer.cancer.gov/explorer/, 2022.
  146. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted mortality rates, 2000-2019, by race/ethnicity, male, all ages. Accessed on April 18, 2022. https://seer.cancer.gov/explorer/, 2022.
  147. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted mortality rates, 2000-2020, by sex, all races, all ages. Accessed on October 11, 2022. https://seer.cancer.gov/explorer/, 2022.
  148. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Long-term trends in SEER age-adjusted mortality rates, 1975-2020, by sex, all races, all ages. Accessed on October 12, 2022. https://seer.cancer.gov/explorer/, 2022.
  149. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – Recent trends in SEER age-adjusted mortality rates, 2000-20120 by race/ethnicity, female, all ages. Accessed on October 11, 2022. https://seer.cancer.gov/explorer/, 2022.
  150. Surveillance Research Program, National Cancer Institute. SEER*Explorer. Breast Cancer – 5-year age-adjusted mortality rates, 2016-2020, by race/ethnicity, female, all ages. Accessed on October 11, 2022. https://seer.cancer.gov/explorer/, 2022.
  151. American Cancer Society. Cancer Facts and Figures 2023. Atlanta, GA: American Cancer Society, 2023.

Updated 01/24/23

TOOLS & RESOURCES

Join the Movement
Find a race or walk near you
Learn More

Need Help or
More Information?

1-877 GO KOMEN
(1-877-465-6636)